Trials / Unknown
UnknownNCT03253068
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
A Phase II Study of Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Wakayama Medical University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus amurubicin (AMR).
Detailed description
Open, uncontrolled, multi-center, phase II study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab plus amurubicin | Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2020-12-28
- Completion
- 2020-12-31
- First posted
- 2017-08-17
- Last updated
- 2020-05-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03253068. Inclusion in this directory is not an endorsement.